Literature DB >> 27641910

Reactive Oxygen Species Impair the Function of CD90+ Hematopoietic Progenitors Generated from Human Pluripotent Stem Cells.

Roger E Rönn1, Carolina Guibentif1, Shobhit Saxena1, Niels-Bjarne Woods1.   

Abstract

Cell stressors, such as elevated levels of reactive oxygen species (ROS), adversely affect hematopoietic stem cell (HSC) reconstituting ability. However, the effects of ROS have not been evaluated in the context of hematopoietic development from human pluripotent stem cells (hPSCs). Using our previously described in vitro system for efficient derivation of hematopoietic cells from hPSCs, we show that the vast majority of generated hematopoietic cells display supraphysiological levels of ROS compared to fresh cord blood cells. Elevated ROS resulted in DNA damage of the CD34+ hematopoietic fraction and, following functional assays, reduced colony formation and impaired proliferative capacity. Interestingly, all the proliferative potential of the most primitive hematopoietic cells was limited to a small fraction with low ROS levels. We show that elevation of ROS in hPSC-derived hematopoietic cells is contributed by multiple distinct cellular processes. Furthermore, by targeting these molecular processes with 4 unique factors, we could reduce ROS levels significantly, yielding a 22-fold increase in the most primitive CD90+ CD34+ hematopoietic cells with robust growth capacity. We demonstrate that the ROS reducing factors specifically reduced ROS in more primitive hematopoietic fractions, in contrast to endothelial cells that maintained low ROS levels in the cultures. We conclude that high levels of ROS in in vitro differentiation systems of hPSCs is a major determinant in the lack of ability to generate hematopoietic cells with similar proliferation/differentiation potential to in vivo hematopoietic progenitors, and suggest that elevated ROS is a significant barrier to generating hPSC-derived repopulating HSCs. Stem Cells 2017;35:197-206.
© 2016 AlphaMed Press.

Entities:  

Keywords:  Functional impairment; Hematopoietic development; Hematopoietic stem cells; Human pluripotent stem cells; Reactive oxygen species

Mesh:

Substances:

Year:  2016        PMID: 27641910     DOI: 10.1002/stem.2503

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  7 in total

Review 1.  The Dual Role of ROS in Hematological Malignancies: Stem Cell Protection and Cancer Cell Metastasis.

Authors:  Azin Samimi; Mohammad Javad Khodayar; Hadis Alidadi; Elahe Khodadi
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

Review 2.  Mitochondria Turnover and Lysosomal Function in Hematopoietic Stem Cell Metabolism.

Authors:  Makiko Mochizuki-Kashio; Hiroko Shiozaki; Toshio Suda; Ayako Nakamura-Ishizu
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

3.  Encapsulation of murine hematopoietic stem and progenitor cells in a thiol-crosslinked maleimide-functionalized gelatin hydrogel.

Authors:  Aidan E Gilchrist; Julio F Serrano; Mai T Ngo; Zona Hrnjak; Sanha Kim; Brendan A C Harley
Journal:  Acta Biomater       Date:  2021-06-20       Impact factor: 10.633

4.  Oxidative stress response induced by chemotherapy in leukemia treatment.

Authors:  Jin Zhang; Wen Lei; Xiaohui Chen; Shibing Wang; Wenbin Qian
Journal:  Mol Clin Oncol       Date:  2018-01-10

Review 5.  The Genomic Health of Human Pluripotent Stem Cells: Genomic Instability and the Consequences on Nuclear Organization.

Authors:  Marianne P Henry; J Ross Hawkins; Jennifer Boyle; Joanna M Bridger
Journal:  Front Genet       Date:  2019-01-21       Impact factor: 4.599

Review 6.  Reactive Oxygen Species and Nrf2: Functional and Transcriptional Regulators of Hematopoiesis.

Authors:  Linping Hu; Yawen Zhang; Weimin Miao; Tao Cheng
Journal:  Oxid Med Cell Longev       Date:  2019-11-18       Impact factor: 6.543

7.  Different subsets of haematopoietic cells and immune cells in bone marrow between young and older donors.

Authors:  W-L Yao; Q Wen; H-Y Zhao; S-Q Tang; Y-Y Zhang; Y Wang; L-P Xu; X-H Zhang; X-J Huang; Y Kong
Journal:  Clin Exp Immunol       Date:  2020-10-21       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.